FMR1 and the fragile X syndrome: Human genome epidemiology review

Genetics in Medicine

Volumn 3, Issue 5, 2001, Pages 359-371

  Crawford, Dana C ^a   Acuña, Juan M ^a   Sherman, Stephanie L ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Epidemiology; FMR1; Fragile X syndrome; FRAXA; Mental retardation; Review

Indexed keywords

FRAGILE X MENTAL RETARDATION PROTEIN;

5' UNTRANSLATED REGION; CAUCASIAN; DISEASE CARRIER; DISEASE SEVERITY; EPIDEMIOLOGICAL DATA; ETHNIC AND RACIAL GROUPS; FEMALE; FRAGILE X SYNDROME; GENE AMPLIFICATION; GENE LOCATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC SCREENING; GENOME ANALYSIS; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HUMAN; HUMAN GENOME; MALE; MEDICAL INFORMATION; MENTAL RETARDATION MALFORMATION SYNDROME; PHENOTYPE; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; POPULATION RISK; PREVALENCE; RACE DIFFERENCE; REVIEW; SEX DIFFERENCE; SOUTHERN BLOTTING; TREATMENT PLANNING; X CHROMOSOMAL INHERITANCE; X CHROMOSOME LINKED DISORDER;

EID: 0035746538     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/00125817-200109000-00006     Document Type: Review

References (155)

1. Human and murine FMR-1: Alternative splicing and translational initiation down-stream of the CGG repeat
2. Fine structure of the human FMR1 gene
3. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome
4. FXR1, an autosomal homolog of the fragile X mental retardation gene
5. The chicken FMR1 gene is highly conserved with a CCT 5′-untranslated repeat and encodes an RNA-binding protein
6. Characterization of dFMR1, a Drosophila melanogaster homolog of the fragile X mental retardation protein
7. Tissue specific expression of FMR-1 provides evidence for a functional role in fragile X syndrome
8. The fragile X syndrome
9. The protein product of the fragile X gene, FMR1, has characteristics of an RNA-binding protein
10. Specific sequences in the fragile X syndrome protein FMR1 and the FXR proteins mediate their binding to 60S ribosomal subunits and the interactions among them
11. Differential expression of FMR1, FXR1 and FXR2 proteins in human brain and testis
12. Different targets for the fragile X-related proteins revealed by their distinct nuclear localizations
13. Oligomerization properties of fragile-X mental-retardation protein (FMRP) and the fragile-X-related proteins FXR1P and FXR2P
14. Evidence that fragile X mental retardation protein is a negative regulator of translation
15. The fragile X mental retardation protein is a ribonucleoprotein containing both nuclear localization and nuclear export signals
16. The fragile X mental retardation protein is associated with poly(A) + mRNA in actively translating polyribosomes
17. FMRP is associated to the ribosomes via RNA
18. Isolation of an FMRP-associated messenger ribonucleoprotein particle and identification of nucleolin and the fragile X-related proteins as components of the complex
19. A novel RNA-binding nuclear protein that interacts with the fragile X mental retardation (FMR1) protein
20. The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutations
21. Characterization and localization of the FMR-1 gene product associated with fragile X syndrome
22. Fragile X mental retardation protein: Nucleocytoplasmic shuttling and association with somatodendritic ribosomes
23. Familial transmission of the FMR1 CGG repeat
24. Technical standards and guidelines for fragile X: The first of a series of disease-specific supplements to the standards and guidelines for Clin Genet Laboratories of the American College of Medical Genetics
25. Examination of factors associated with instability of the FMR1 CGG repeat
26. The risk of fragile X premutation expansion is lower in carriers detected by general prenatal screening than in carriers from known fragile X families
27. Characterization of the full fragile X syndrome mutation in fetal gametes
28. Transition from premutation to full mutation in fragile X syndrome is likely to be prezygotic
29. The full mutation in the FMR-1 gene of male fragile X patients is absent in their sperm
30. DNA methylation represses FMR-1 transcription in fragile X syndrome
31. Acetylated histones are associated with FMR1 in normal but not fragile X syndrome cells
32. Absences of expression of the FMR-1 gene in fragile X syndrome
33. Variation of the CGG repeat at the fragile X site results in genetic instability: Resolution of the Sherman paradox
34. Fragile sites on human chromosomes: Demonstration of their dependence on the type of tissue culture medium
35. The frequency of the fragile X chromosome among schoolchildren in Coventry
36. Preventive screening for the fragile X syndrome
37. Prevalence of fragile X syndrome
38. Prevalence of the fragile X syndrome in African Americans
39. Population studies of the fragile X: A molecular approach
40. Molecular screening of fragile X (FRAXA) and FRAXE mental retardation syndromes in the Hellenic population of Greece and Cyprus: Incidence, genetic variation, and stability
41. FRAXA and FRAXE: The results of a five year survey
42. Frequency of Fra X syndrome among institutionalized mentally retarded males in Poland
43. Screening for FMR1 mutations among the mentally retarded: Prevalence of the fragile X syndrome in Spain
44. DNA testing for fragile X syndrome in schools for learning difficulties
45. FRAXA locus in fragile X diagnosis: Family studies, prenatal diagnosis, and diagnosis of sporadic cases of mental retardation
46. The prevalence of the FMR1 and FMR2 mutations among preschool children with language delay
47. Screening and diagnosis for the fragile X syndrome among the mentally retarded: An epidemiological and psychological survey
48. Fragile X. Syndrome: New developments
49. Prevalence of fragile X syndrome
50. Fragile X syndrome screening: A current opinion
51. Predisposition to the fragile X syndrome in Jews of Tunisian descent is due to the absence of AGG interruptions on a rare Mediterranean haplotype
52. FMR1 in global populations
53. A survey of fragile X syndrome in a sample from Spanish Basque country
54. Stability of the FMR1 CGG repeat in a Basque sample
55. Absence of fragile X syndrome in Nova Scotia
56. Prevalence of fragile X syndrome and FRAXE among children with intellectual disability in a Caribbean island, Guadeloupe, French West Indies
57. Screening for fragile X syndrome in women of reproductive age
58. An introduction to applied probability
59. The role of size, sequence and haplotype in the stability of FRAXA and FRAXE alleles during transmission
60. Prevalence of carriers of premutation-size alleles of the FMR1 gene-and implications for the population genetics of the fragile X syndrome
61. Increased transmission of intermediate alleles of the FMR1 gene compared with normal alleles among female heterozygotes
62. Molecular fragile X screening in normal populations
63. Feasibility and acceptance of screening for fragile X mutations in low-risk pregnancies
64. A pedigree of mental defect showing sex-linkage
65. Advances in research on the fragile X syndrome
66. Early developmental trajectories of males with fragile X syndrome
67. Physical and behavioral phenotype
68. Autistic behavior in young boys with fragile X syndrome
69. Variable expression of the fragile X syndrome in heterozygous females of normal intelligence
70. A multicenter study on genotype-phenotype correlations in fragile X syndrome, using direct diagnosis with probe StB128: The first 2,253 cases
71. Mental status of females with an FMR1 gene full mutation
72. Neurobehavioral effects of the fragile X premutation in adult women: A controlled study
73. A study of the physical, behavioral, and medical phenotype, including anthropometric measures, of females with the fragile X syndrome
74. The neurocognitive phenotype of female carriers of fragile X: Additional evidence for specificity
75. Transmitting males and carrier females in fragile X-revisited
76. Tissue-specific methylation differences and cognitive function in fragile X premutation females
77. Fragile-X carrier females: Evidence for a distinct psychopathological phenotype?
78. Phenotypic involvement in females with the FMR1 gene mutation
79. Genotype-phenotype relationship in female carriers of the premutation and full mutation of FMR-1
80. Elevated levels of FMR1 mRNA in carrier males: A new mechanism of involvement in the fragile X syndrome
81. Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers
82. Transcription of the FMR1 gene in individuals with fragile X syndrome
83. Premature ovarian failure in the fragile X syndrome
84. Monozygotic twin brothers with the fragile X syndrome: Different CGG repeat and different mental capacities
85. Twin sisters, monozygotic with the fragile X mutations, but with a different phenotype
86. Monozygotic boys with fragile X syndrome
87. FMRP expression as a potential prognostic indicator in fragile X syndrome
88. Cognitive and behavioral profile of fragile X boys: Correlations to molecular data
89. Autistic behavior, FMR1 protein, and developmental trajectories in young males with fragile X syndrome
90. Fragile X full mutations are more similar in siblings than in unrelated patients: Further evidence for a familial factor in CGG repeat dynamics
91. FMR1 CGG-repeat instability in single sperm and lymphocytes of fragile-X premutation males
92. Factors involved in the initial mutation of the fragile X CGG repeat as determined by sperm small pool PCR
93. Screening for fragile X syndrome: Information needs for health planners
94. Mutational analysis of the FMR1 gene in 118 mentally retarded males suspected of fragile X syndrome: Absence of prevalent mutations
95. Rapid antibody test for fragile X syndrome
96. Rapid antibody test for diagnosing fragile X syndrome: A validation of the technique
97. Screening with the FMR1 protein test among mentally retarded males
98. Noninvasive test for fragile X syndrome, using hair root analysis
99. Screening for the fragile X syndrome among mentally retarded males by hair root analysis
100. Prenatal fragile X detection using cytoplasmic and nuclear-specific monoclonal antibodies
101. Rapid FMR1-protein analysis of fetal blood: An enhancement of prenatal diagnostics
102. Fragile X syndrome: Diagnostic and carrier testing
103. Evaluation of mental retardation: Recommendations of a consensus conference
104. A 6-year experience demonstrates the utility of screening for both cytogenetic and FMR-1 abnormalities in patients with mental retardation
105. Outcome of the routine assessment of patients with mental retardation in a genetics clinic
106. Problems in the diagnosis of fragile X syndrome in young children are still present
107. Physical characteristics of young boys with fragile X syndrome: Reasons for difficulties in making a diagnosis in young males
108. Fragile X. Syndrome: Incidence, clinical and cytogenetic findings in the black and white populations of South Carolina
109. Effects of child age and level of developmental delay on family practice physicians' diagnostic impressions
110. Family experiences and factors associated with the diagnosis of fragile X syndrome
111. Prenatal diagnosis and carrier screening for fragile X by PCR
112. Fragile X screening in pediatric and obstetrical patients
113. A five-year experience with fragile X screening of high-risk gravid women
114. Prenatal diagnosis of fragile X syndrome and the risk of expansion of a premutation
115. Informed choice in fragile X syndrome and its effects on prevalence
116. Serving the family from birth to the medical home. A report from the newborn screening task force convened in Washington DC, May 10-11, 1999
117. Cost effectiveness of DNA diagnosis for four monogenic diseases
118. Explorative study of costs, effects and savings of screening for female fragile X premutation and full mutation carriers in the general population
119. Identifying infants and toddlers with fragile X syndrome: Issues and recommendations
120. Efficacy of cascade testing for fragile X syndrome
121. Population screening at the FRAXA and FRAXE loci: Molecular analyses of boys with learning difficulties and their mothers
122. Prevalence and phenotype consequence of FRAXA and FRAXE alleles in a large, ethnically diverse, special education-needs population
123. Systematic screening for fragile X syndrome in a cohort of 574 mentally retarded children
124. Frequency of the fragile X syndrome in Chinese mentally retarded populations is similar to that in Caucasians
125. Prevalence of fragile X(A) syndrome in mentally retarded children at a genetics referral centre in Delhi, India
126. Applicability of a checklist for clinical screening of the fragile X syndrome
127. Evaluation of school children at high risk for fragile X syndrome utilizing buccal cell FMR-1 testing
128. Comparison between the cytogenetic test for fragile X and the molecular analysis of the FMR-1 gene in Japanese mentally retarded individuals
129. Molecular screening for fragile X syndrome among Indonesian children with developmental disability
130. FRAXA and FRAXE prevalence in patients with nonspecific mental retardation in the Hellenic population
131. Fully mutated and gray-zone FRAXA alleles in Brazilian mentally retarded boys
132. Non-radioactive DNA. Diagnosis for the fragile X syndrome in mentally retarded Japanese males
133. DNA testing for fragile X syndrome in 255 males from special schools in Singapore
134. Trinucleotide CGG repeat in the FMR1 gene in Chinese mentally retarded patients
135. Fragile X syndrome is less common than previously estimated
136. Fragile X syndrome. Clinical analysis of 200 Chilean patients with unspecific mental retardation
137. Implication of screening for FMR1 and FMR2 gene mutation in individuals with nonspecific mental retardation in Taiwan
138. DNA diagnosis of the fragile X syndrome in a series of 236 mentally retarded subjects and evidence for a reversal of mutation in the FMR-1 gene
139. Direct mutation analysis of 495 patients for fragile X carrier status/proband diagnosis
140. Screening for FMR1 and FMR2 mutations in 222 individuals from Spanish special schools: Identification of a case of FRAXE-associated mental retardation
141. Frequency of fragile X syndrome among Turkish patients with mental retardation of unknown etiology
142. Fragile X syndrome occurs in the South African black population
143. Molecular evidence that fragile X syndrome occurs in the South African black population
144. The prevalence of fragile X syndrome in an institution for people with learning disability
145. Prevalence and clinical characteristics of fragile X syndrome at child development clinic, Ramathibodi hospital
146. Expansion mutation frequency and CGG/GCC repeat polymorphism in FMR1 and FMR2 genes in an Indian population
147. Fragile X checklist
148. FRAXA screening in Brazilian institutionalized individuals with nonspecific severe mental retardation
149. DNA analysis of the fragile X syndrome in an at risk pediatric population in Croatia: Simple clinical preselection criteria can considerably improve the cost-effectiveness of fragile X screening studies
150. Molecular diagnosis of the fragile X and FRAXE syndromes in patients with mental retardation of unknown cause in Mexico
151. Distribution and frequency of FMR1 CGG repeat numbers in the general population
152. Frequency of FMR1 premutations in a consecutive newborn population by PCR screening of Guthrie blood spots
153. Frequency and stability of the fragile X premutation
154. The FMR1 and FMR2 mutations are not common etiologies of academic difficulty among school-age children
155. Analysis of a CGG sequence at the FMR-1 locus in fragile X families and in the general population